Adam Haney

Adam Haney is a US-based solo angel investing at pre-seed and seed with checks under $250K. His focus is artificial intelligence and natural language processing, reflecting his own technical background, and he backs founders building applied AI, infrastructure, and software products with serious technical depth. He is not a healthcare investor by stated focus, and any healthcare investment would be incidental to a broader AI thesis rather than the core reason for the deal.

The thesis centers on AI and machine learning, with particular attention to natural language processing, applied AI products, and developer tooling. Adam tends to back B2B software companies and infrastructure plays where the technical work is hard and the founder’s command of the underlying problem is evident. Healthcare-specific opportunities are not part of his stated mandate, though he could engage with companies where a healthcare use case happens to sit on top of an AI infrastructure or NLP foundation that he finds compelling on its technical merits.

As a solo angel writing under $250K, Adam participates in rounds led by institutional VCs or other angels and is rarely the lead investor. The geographic focus is the United States, where most of his activity is concentrated. He invests in pre-seed and seed rounds and is willing to back pre-revenue companies if the team is strong and the technical wedge is clear. Founders should expect quick decisions and a willingness to engage on technical questions, but they should not look to him as a check-setting investor or as someone who will provide formal governance support.

There is no fund team or associated firm. Adam operates on his own balance sheet and engages directly with founders. The relationship is what it appears to be: an experienced technical operator with capital who can offer pattern matching on AI products, technical review, and introductions within his network of operators and angels.

His working style is informal and engagement-driven. He typically does not take board seats and adds value through technical conversations, hiring introductions, and warm referrals to other investors and operators. For founders building AI or NLP-first products who want a technically engaged angel on a cap table dominated by institutional investors, Adam can be a useful early signal and a source of practical help. Founders building healthcare-specific products without a strong technical AI core will find less alignment with his focus, and a clean redirection toward a more relevant investor is often the right outcome of an early conversation.